Viewing nowCombinationLipomin Duo Sustained Release Tablets 5/1000 mg (Linagliptin, Metformin Hydrochloride)
Metformin Hydrochloride 1000mg · Linagliptin Micronized 5mg
Tablet · Prescription medication · Combination
Daehan New Pharm Co., Ltd.

MFDS item code 202400615 · Approved 2024.03.22 · Insurance code 669908390
Improvement of glycemic control in patients with type 2 diabetes mellitus
This medication is used to aid blood sugar control in patients with type 2 diabetes, in conjunction with diet and exercise therapy, by utilizing both linagliptin and metformin. It effectively lowers blood sugar levels and helps manage diabetes.
The dose of this medication for antidiabetic therapy should be determined based on each patient's current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended daily doses of each component: linagliptin 5mg and metformin hydrochloride extended-release 2000 mg. This medication should be taken once daily with a meal, preferably with the evening meal. To reduce gastrointestinal adverse reactions associated with metformin use, the dose of metformin hydrochloride should be increased gradually. To maintain its extended-release properties, this medication should be swallowed whole and not split, crushed, ground, or chewed. The 5/1000 mg extended-release tablet of this medication should be taken once daily as 1 tablet per dose. Patients taking the 2.5/1000 mg extended-release tablets of this medication should take 2 tablets together once daily. 1. Patients not currently receiving metformin: The initial dose of this medication is a total daily dose of linagliptin 5 mg and metformin hydrochloride 1000mg. The dose of metformin hydrochloride may be gradually increased up to the maximum recommended daily dose of 2000 mg. 2. Patients receiving metformin - For patients who cannot achieve adequate glycemic control with metformin monotherapy, the initial dose of this medication is a total daily dose of linagliptin 5 mg and the patient's current dose of metformin hydrochloride. - For patients who cannot achieve adequate glycemic control with combination therapy of metformin and a sulfonylurea, or metformin and insulin, an initial dose of this medication consisting of a total daily dose of linagliptin 5mg and a dose of metformin hydrochloride similar to the patient's current dose should be considered. When this medication is administered concomitantly with insulin or a sulfonylurea, a reduction in the dose of insulin or the sulfonylurea may be necessary to reduce the risk of hypoglycemia. - When switching from an immediate-release metformin formulation to an extended-release formulation, glycemic control should be closely monitored and the dose adjusted appropriately if necessary. - When switching from combination therapy with linagliptin and extended-release metformin to this medication, the dose of this medication is the patient's current dose of linagliptin and extended-release metformin hydrochloride. Renal impairment Because dose adjustment according to renal function is necessary, assessment of renal function is recommended before starting this medication and periodically during treatment. No dose adjustment of this medication is necessary in patients with mild renal impairment [creatinine clearance (CrCl) ≧ 60mL/min or estimated glomerular filtration rate (eGFR) ≧ 60mL/min/1.73 m2]. In patients with moderate renal impairment (CKD stage 3A), with creatinine clearance (CrCl) of 45mL/min or more and less than 60mL/min, or estimated glomerular filtration rate (eGFR) of 45mL/min/1.73m2 or more and less than 60mL/min/1.73m2, who tolerate treatment well and have no other conditions that may increase the risk of lactic acidosis, this medication may be used with adjustment of the metformin hydrochloride dose as follows. The starting dose of metformin hydrochloride is 500mg or 750mg once daily; therefore, treatment should not be initiated with this medication. The maximum daily dose of metformin hydrochloride is 1000mg. If creatinine clearance (CrCl) falls below 45mL/min or estimated glomerular filtration rate (eGFR) falls below 45mL/min/1.73m2, this medication should be discontinued immediately.
This medication is used to control blood sugar levels and contains two active ingredients. While taking this medication, there is a rare chance that a serious condition known as lactic acidosis may occur, requiring immediate treatment. Patients with severely impaired kidney function or acute kidney dysfunction should not use this medication. Additionally, it should not be administered to patients with type 1 diabetes, diabetic ketoacidosis, or diabetic precoma. It is also safe to avoid this medication during acute illnesses such as severe infections, shock, or acute myocardial infarction. Patients with liver dysfunction or severe gastrointestinal disorders, as well as those in acute alcohol intoxication, should also avoid this medication. Pregnant women or those with placenta-related issues should also refrain from using this medication. When using this medication in combination with other blood sugar-lowering agents, there is a risk of hypoglycemia, so caution is advised, particularly if used with sulfonylureas or insulin, which may require dose adjustments. Gastrointestinal disturbances, diarrhea, abdominal pain, or loss of appetite may occur while taking this medication; if symptoms are severe, consult a doctor. Rare side effects like acute pancreatitis or erythema multiforme may occur; if such symptoms appear, stop taking the medication immediately and visit a hospital. Long-term use may cause decreased vitamin B12 levels, necessitating regular blood tests. This medication should be swallowed whole and not crushed or chewed; the shell of the tablet may be excreted in the stool, which is normal. Patients with impaired kidney function or the elderly should particularly have their kidney function checked regularly and adjust doses as necessary. If iodinated contrast agents are used for radiological examinations, this medication should be temporarily discontinued before and after the examination, and kidney function should be assessed before resuming use. Patients undergoing surgery should discontinue this medication 48 hours before surgery and resume after kidney function has recovered post-surgery. The risk of lactic acidosis increases with alcohol consumption, so avoid drinking alcohol. When taking this medication in conjunction with other drugs, there may be interactions, so inform your healthcare provider or pharmacist about all medications being taken. Pregnant or breastfeeding women should avoid using this medication, and those planning to become pregnant should consult a healthcare provider. Safety for use in children has not been established, so it should not be used in pediatric patients. Data on the effects on driving or operating machinery is lacking; caution is advised. In the case of overdose, the medication may not be completely absorbed in the gastrointestinal tract, but serious lactic acidosis can occur, necessitating immediate hospital visit. Store this medication out of reach of children, away from moisture, and do not transfer to other containers.
Not everyone experiences these, and they can vary from person to person.
Store this medication in a tightly sealed container to prevent air or moisture from entering, preferably at room temperature between 1 and 30 degrees Celsius. Keeping it stored this way will help maintain its effectiveness and safety.
Oval sustained release tablet, white to almost white, engraved with DN51 on one side
28 tablets/box [7 tablets/PTP x 4], 30 tablets/bottle
Even with the same ingredient, strength, dosage form and how it is taken can differ.
Viewing nowCombinationMetformin Hydrochloride 1000mg · Linagliptin Micronized 5mg
Tablet · Prescription medication · Combination
Daehan New Pharm Co., Ltd.
Linagliptin Micronized 2.5mg · Metformin Hydrochloride 1000mg
Tablet · Prescription medication · Combination
Samjin Pharmaceutical Co., Ltd.
Linagliptin Micronized 2.5mg · Metformin Hydrochloride 500mg
Tablet · Prescription medication · Combination
Samjin Pharmaceutical Co., Ltd.
Linagliptin Micronized 2.5mg · Metformin Hydrochloride 850mg
Tablet · Prescription medication · Combination
Samjin Pharmaceutical Co., Ltd.
CombinationLinagliptin Micronized 2.5mg · Metformin Hydrochloride 500mg
Tablet · Prescription medication · Combination
Genewon Science Co., Ltd.
CombinationLinagliptin Micronized 2.5mg · Metformin Hydrochloride 1000mg
Tablet · Prescription medication · Combination
Genewon Science Co., Ltd.
CombinationLinagliptin Micronized 5mg · Metformin Hydrochloride 1000mg
Tablet · Prescription medication · Combination
Genewon Science Co., Ltd.
CombinationLinagliptin Micronized 2.5mg · Metformin Hydrochloride 1000mg
Tablet · Prescription medication · Combination
Genewon Science Co., Ltd.
Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.
No questions yet.
For anything that needs medical judgment, consult a doctor or pharmacist.
This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.